Type 1 diabetes (DT1) and type 2 diabetes (DT2) are both well-established risk factors for cardiovascular disease, but their underlying mechanisms differ significantly. While type 1 diabetes results from an insulin deficit, often referred to as “insulin-dependent” diabetes, type 2 diabetes is characterized by tissue insensitivity to insulin, particularly in muscles.

The Risks of Coronaropathy, Stroke, etc.: How Do They Differ?

To gain a clearer understanding, a major American study was conducted, focusing on patients aged 46 to 75 with DT1 or DT2, who had no prior cardiovascular history. The study tracked patients in ambulatory care settings, including general medicine and endocrinology, and those registered in the Veradigm Metabolic Registry between 2017 and 2022.

Operated in collaboration with the American College of Cardiology, the registry contains monitoring files of 1.5 million individuals from over 700 institutions. The study encompassed 5,823 patients with DT1 (3.59%) and 156,204 patients with DT2 (95.41%), resulting in a total of 758,643 consultations.

As anticipated, patients with DT1 were generally younger and exhibited fewer associated diseases such as renal and cardiovascular comorbidities.

Comparison of Cardiovascular Events

The researchers analyzed the frequency of various cardiovascular events over a five-year period, including myocardial infarction, the need for coronary angioplasty (dilation of the artery with the possible installation of a stent), coronary artery bypass grafting (CABG), stroke, and revascularization of carotid and peripheral arteries.

These interventions are crucial for restoring and maintaining blood flow in obstructed or narrowed arteries, including those in the lower limbs.

Cardiovascular Risk Varies by Diabetes Type

The findings led to significant insights, including the realization that the cardiovascular risk associated with type 1 diabetes is lower than previously estimated. “Researchers suggested that The cardiovascular risk associated with type 1 diabetes is lower than was previously estimated. They indicate that type 1 diabetes is associated with a lower risk of cardiovascular events compared to type 2 diabetes, even after adjustments for factors such as age, diabetes control, and kidney function. The power of large data strengthens the results, thanks to the enormous population included in this analysis,” noted the lead researchers.

A total of 11,096 incident cardiovascular events were identified. At equivalent ages, people with type 1 diabetes exhibited about 33% less risk of experiencing a cardiovascular event compared to those with type 2 diabetes.

Lower Risks of Myocardial Infarction in Type 1 Diabetes

A detailed analysis showed that DT1 was associated with a lower frequency of myocardial infarction, coronary angioplasty, stroke, and peripheral ischemia compared to DT2. This trend remained consistent across all age groups, in both men and women, before and after the COVID-19 pandemic. It also held true after accounting for the presence of comorbidities, blood sugar levels (expressed as HbA1C), and serum creatinine levels (a marker of renal function).

Conversely, the risk of CABG, carotid revascularization, and peripheral revascularization did not differ based on the type of diabetes.

Mechanisms and Management Strategies Remain Elusive

DR. Bracha Goldsweig, an endocrinologist and study co-author, emphasized, “People with type 1 diabetes now live a normal life expectancy, and it is essential to study this population to ensure they receive the best possible care.” The underlying mechanisms, as well as the prevention and management strategies of cardiovascular complications in DT1 patients, remain poorly understood.

Further Research Needed on Type 1 Diabetes and Cardiovascular Consequences

Type 1 diabetes has historically been overlooked in research on cardiovascular complications, as highlighted in a joint statement by the American Heart Association and the American Diabetes Association.

The management of cardiovascular diseases associated with type 1 diabetes often relies on studies conducted on type 2 diabetes patients, despite the distinct nature and evolutionary trajectories of these two diseases.

Proposed factors contributing to atherogenesis, such as hyperglycemia, insulin resistance, dyslipidemia, inflammation, oxidative stress, endothelial dysfunction, and vascular calcification, differ between the two types of diabetes. However, the exact mechanisms behind these processes have yet to be fully explored.

Future research will need to examine the unique mechanisms at play in atherogenesis between the two types of diabetes. Consider the differences as highlighted by these case studies:

• John, a 43-year-old man with type 1 diabetes, underwent coronary angioplasty after experiencing angina symptoms. His management involved careful monitoring of blood sugar and cardiovascular risk factors, reflecting the personalized approach needed for DT1 patients.
• Maria, a 60-year-old woman with type 2 diabetes, required a carotid revascularization procedure due to severe atherosclerosis. Her treatment plan focused on lifestyle modifications, medications, and regular follow-ups, emphasizing the holistic care required for DT2 patients.
• This highlights the discrepancy in management and the dire need of rethinking the clinical strategies.

Future research will need to study the distinct risks and management strategies for patients with type 1 and type 2 diabetes to ensure optimal care and outcomes.

HealthyLife Potential Treatments and Innovations

Recent advancements in medical technology, such as continuous glucose monitoring (CGM) and automated insulin delivery systems, offer promising avenues for managing type 1 diabetes.

The Updated Diabetes Screening Guidelines issues a new error forecasting algorithm designed to predict cardiovascular risk in patients with type 1 and type 2 diabetes. Similar to the circular metrics system utilized by NASA for their space missions, this algorithm considers a multitude of variables, including glucose levels, inflammation markers, and genetic predispositions, providing a more accurate assessment of an individual’s cardiovascular risk.

Conclusion

While both types of diabetes pose significant cardiovascular risks, the specific mechanisms and management strategies differ. Ongoing research and technological advancements hold promise for improving the lives of individuals with diabetes, ensuring they receive the best possible care.